Related Experiment Videos
Nicotine for Alzheimer's disease.
J M López-Arrieta1, J L Rodríguez, F Sanz
1Hospital de Cantoblanco, Consejería de Sanidad, Carretera de Colmenar km 14.500, Madrid, Madrid, Spain, 28049. med013440@nacom.es
The Cochrane Database of Systematic Reviews
|May 5, 2000
Summary
This review found no reliable evidence that nicotine benefits Alzheimer's disease (AD) patients. Due to poor trial quality and limited data, nicotine's efficacy and safety for AD remain uncertain.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Nicotine, a cholinergic agonist, shows potential in animal models for reversing memory decline.
- Nicotine affects neurotransmitters like serotonin, dopamine, and GABA.
- Concerns exist regarding nicotine's adverse effects, including cardiovascular risks and sleep disturbances, particularly in the elderly.
Purpose of the Study:
- To systematically review the clinical efficacy of nicotine for Alzheimer's disease (AD).
- To assess the safety profile of nicotine use in patients with AD.
Main Methods:
- A systematic search of the Cochrane Controlled Trials Register was conducted using terms related to nicotine and Alzheimer's disease.
- Inclusion criteria specified unconfounded, double-blind, randomized trials comparing nicotine administration (patches or intravenous) for over a day against a placebo in AD patients.
- No trials met the inclusion criteria for data extraction or meta-analysis; one trial is pending assessment.
Main Results:
- The quality of available trials was insufficient for synthesizing results.
- Data from considered trials suggest nicotine may cause harm, no change, or improvement, but this is inconclusive.
Conclusions:
- Current evidence is insufficient to establish nicotine as a beneficial treatment for Alzheimer's disease.
- Further high-quality research is needed to determine nicotine's role in AD management.